Background and aims: Skeletal muscle catabolism is a co-morbidity of many
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One of the important challenges developed in the last decades and could affect health is the population exposure to electromagnetic waves (EMW), particularly the 'Global System of Mobile Communication signals', GSM signals. These GSM signals are emitted from many sources as like cell phones and base stations antenna. Our study investigates the effects of EMW radiation emitted from GSM mobile phones antenna (frequency at 900 MHz, Eeff025 V/m) on extensor digitorum longus (edl) muscle myofibrillar proteins. Results show that animals body weight was not affected by 6 weeks of continuous 24-h exposure, but edl absolute muscle mass was increased by 10.5%
(control: 0.1744±0.00252, exposed: 0.1927±0.00291, n012, p<0.05).
Since myofibrillar proteins content is directly proportional to muscle mass, protein dosage using the Bradford technique was performed and protein concentration was calculated in mg/g of muscle. An increase by 59% in edl myofibrillar protein content after the period of exposure was observed (control 20.11±1.59, exposed 31.97±2.81, n012, p 
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Role of lipases in cancer-associated cachexia Background and aims: Skeletal muscle atrophy is characterized by a decrease in muscle mass and force. In the drug discovery for muscle atrophy, muscle hypertrophy or increased muscle mass can be easily monitored using cellular or animal model rather than force measurement. However, since previous researches have implicated that muscle force measurement is important for monitoring the effect of treatment in muscle atrophy, we tried to establish in vitro muscle force measurement system, myotransducer.
Methods: Electro pulse stimulation (EPS) of C2C12 cells was used for in vitro muscle force model. C2C12 cells were seeded on collagen membranes and differentiated to myotube (myosheet) then EPS (0.5 V, 0.5 Hz) was applied until maximal tetanus force (max-force) of myosheet reached to stable state. IGF-1 and dexamethasone (DEX) were added in order to induce for hypertrophy or atrophy and time course of max-force was monitored.
Results: After 10-days EPS treatment, IGF-1 myosheets showed hypertrophic feature and its max-force was significantly higher than control. DEX induced myotube disruption and its max-force was diminished. This was accompanied by increased mRNA expression of atrogin-1, MuRF-1 and Cbl-b. When EPS loading was decreased (0.5~0.05 V), max force was also reduced in a voltage intensity dependent manner, but IGF-1 treatment had still higher max force than control. Moreover, when EPS reloaded at higher level, max-force of IGF-1 myosheets was rapidly recovered up to initial level before voltage lowering started. At the end point of EPS, atrogin-1 and MuRF-1 mRNA expressions were suppressed by IGF-1 treatment. These results are similar to IGF-1 treatment on in vivo muscles atrophy.
Conclusions: Our in vitro system, myotransducer, could detect difference of muscle force by voltage loading (hypertrophy) and unloading (atrophy), and drug treatments (IGF-1 and glucocorticoid). These results suggest that myotransducer may be useful to estimate muscle force in vivo.
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Ghrelin secretion and anxiety in a rat model of anorexia-cachexia induced by methotrexate chemotherapy University, Kagoshima, Japan)
Background and aims: Peripheral acylated ghrelin has orexigenic and anxiolytic effects, but its expression in the brain and putative roles are uncertain. Here, we studied if peripheral and central ghrelin expressions are altered in chemotherapy-associated anorexia-cachexia.
Methods: Preproghrelin and GOAT mRNA were assayed in the stomach, hypothalamus and amygdala and plasma acyl-and des-acyl-ghrelin were measured in Sprague-Dawley rats treated with methotrexate (MTX, 2.5 mg/kg, SC for 3 days). Forced-swim (FST) and elevated plus maze (EPM) tests and tissues sampling were performed at day 5 after first MTX injection, corresponding to the maximal decrease in food and water intakes and a loss of 25% of body weight. Control rats received PBS; the EPM test was done in a separate series of rats.
Results: Preproghrelin mRNA expression levels were lower in the stomach but increased in the hypothalamus of MTX rats. GOAT mRNA was decreased in the stomach and amygdala but not in the hypothalamus of MTX rats. Plasma levels of acyl-and des-acyl ghrelin did not differ significantly from controls but acyl-/des-acyl ghrelin ratios was lower in MTX rats. No significant differences in FST were observed between MTX and control rats, but fewer entries in open and central zone of the EPM were found in MTX rats.
Conclusions: These data show that the hypothalamic preproghrelin gene expression is increased during MTX-induced anorexia. Considering activation of hypothalamic neurosecretory vasopressin neurons in MTX-treated rats (Hamze-Sinno M. et al.; Physiol Behav, 2010) , and immunohistochemical detection of ghrelin in magnocellular neurons (own unpublished results), these data suggest that both acyl-and des-acyl-ghrelin can be secreted from the hypothalamus into the systemic circulation in order to compensate loss of gastric ghrelin and/or to counteract dehydration. However, the lower rates of acylation of systemic ghrelin in MTX rats may contribute to anorexia-cachexia and increased anxiety. pressure-overload-induced heart failure, whereas cardiomyocyte-specific overexpression of the miR-212/132 family leads to impaired autophagic activity, pathological cardiac hypertrophy, heart failure, and finally increased lethality in mice. Mechanistically, both miR-212 and miR-132 directly target the anti-hypertrophic and pro-autophagic FoxO3 transcription factor and overexpression of these miRNAs leads to hyperactivation of pro-hypertrophic calcineurin/NFAT signalling and impaired autophagic response upon starvation. Pharmacologic inhibition of miR-132 by antagomir injection rescues cardiac hypertrophy and heart failure in mice, offering a possible therapeutic approach for cardiac failure.
Conclusions:
The miRNA-212/132 family plays a dominant role in the development of cardiac hypertrophy and heart failure and serves as a novel therapeutic relevant target.
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Angiotensin II upregulates Pp2cα and inhibits AMPK signaling and energy balance leading to skeletal muscle wasting Conclusions: These results demonstrate critical roles for energy depletion and AMPK inhibition in Ang II-induced muscle wasting, and demonstrate a role for AMPK activation in IGF-1 mediated rescue from Ang II wasting.
These findings suggest a therapeutic potential for AMPK activators in diseases characterized by muscle wasting.
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Signaling in the heart of rats with cancer cachexia compared myocardial infarction and fibrosis in the heart using fluorogenic and Luminex assays.
Furthermore, we analysed atrophic proteins and anabolic signaling pathways by Western Blot.
Results: Myocardial infarction of rats caused an impaired heart function without the induction of true cachexia. We found neither apoptosis nor an increase in catabolic signaling, but a rise in the anabolic signaling in the heart. The rat cancer model caused severe cachexia with a strongly impaired cardiac function. There was a 58% loss of LV mass due to an increased catabolism (UPS-System), more apoptosis (increased activity of caspase-3 and -6), necrosis and a downregulation of the anabolic signaling (Akt, 4EBP1, p70S6K). 0.024). Levels of total and indirect bilirubin were similar in cachectic and noncachectic patients versus controls. Considering all patients, higher levels of direct bilirubin, GT and AP correlated with CVP (direct bilirubin r00.58; GT r00.50; AP: r00.52, all p<0.0001) and PAP (direct bilirubin r00.43, p0
Conclusion
0.0002; GT r00.40, p00.0004; AP r00.35, p00.002). Furthermore, levels of GT and AP correlated with greater hepatic vein diameter (r00.49, p00.008 and r00.55, p00.002). Higher direct bilirubin in these patients correlated positively
with prognostic markers such as hsCRP (r00.24, p<0.01), MR-proADM (r0 0.4, p00.0006), and NYHA class (r00.32, p00.0004).
Conclusion:
Markers of cholestatic liver damage are elevated in patients with cardiac cachexia and correlate with indices suggestive of right heart congestion. This indicates a role of liver congestion in elevation of these cholestatic markers in cardiac cachexia as a clinical feature of CHF.
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Reduced hepatic arterial blood supply in patients with advanced chronic heart failure (CHF) Results: Patients with advanced CHF (NYHA III-IV) showed lower systolic and diastolic blood flow in the hepatic artery compared to patients with milder CHF (NYHA I-II) ( Table 1) . As expected, patients in NYHA III-IV had a higher pulsatility index of portal vein, reflective of higher systemic and liver congestion. However, blood flow volume in the portal vein did not differ significantly between both groups. Among all CHF patients, cachectic patients had the lowest systolic and diastolic flow in hepatic artery (50.5 ± 9.7 vs 84.1± 8.2 mL/min, p 00.03 and 68.9± 18.2 vs 107.3± 11.7 mL/min, p00.096). In CHF patients, we found a positive correlation between systolic flow in the hepatic artery and LVEF (r00.47, p00.01). Diastolic flow in the hepatic artery was positively correlated to postischemic forearm blood flow (r00.42, p00.02), a parameter reflective of vascular resistance and endothelial dysfunction. Furthermore, systolic and diastolic blood flow in the hepatic artery correlated negatively with levels of alkaline phosphatase (p < 0.05, p 00.26),
suggesting a role of reduced arterial flow in liver dysfunction.
Conclusion: Arterial blood supply to the liver is reduced in patients with
advanced CHF and may contribute to cholestatic liver damage in these patients.
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Common cardiac symptoms in chronic diseases: a comparison between patients with heart failure and colorectal cancer concerning heart rate variability, cardiac function and exercise capacity Virchow-Klinikum, Berlin, Germany)
Background: The symptoms fatigue, weight loss, impaired exercise capacity and dyspnea are typically present in patients with chronic heart failure (CHF) as well as in those with colorectal cancer (CRC). We hypothesize that in patients with CRC neuroendocrine activation and autonomic dysfunction may contribute to the typical symptoms of CHF by decoupling of physiologic pathways. have not yet been studied in patients with and without cardiac cachexia.
Methods:
We investigated 65 patients with CHF (LVEF 30±1%, peak VO2
15.2±0.6 mL/kg/min, BMI 28.2±0.6) and 26 control subjects of similar age and gender (LVEF 64±2%, peak VO2 27.3±1.4 mL/kg/min, BMI 26.1±0.8).
Twelve of the patients were cachectic (LVEF 25±2%, peak VO2 12.7±
1.2 mL/kg/min, BMI 25.4±1.5). Intestinal peak systolic blood flow was calculated from peak velocity and vessel diameter of the mesenteric arteries (MA) and celiac trunk (CT) using high-resolution ultrasound and Doppler sonography. We measured bowel wall thickness by transcutaneous sonography. Gastrointestinal symptoms were evaluated by gastrointestinal symptom rating scale.
Results: CHF patients showed a lower mean systolic blood flow in the intestine supplying arteries superior and inferior MA and CT compared to control subjects (351±22 vs. 522±37 mL/min, and 55±4 vs. 93±7 mL/min and 419±33 vs. 672±89 mL/min, all p<0.004). The same applied to the peak systolic blood flow in these three main vessels which was again lower in CHF patients compared to controls ( 
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The myogenic potential is reduced in experimental cancer cachexia 1.4 mL/min/kg, p00.03). informed and consenting elderlies (>65-year-old adults) were recruited and assigned to a sarcopenia patients group defined according to up to date diagnostic criteria and an aged matched control group. Elevated agrin degradation occurs in a substantial subset of sarcopenia patients and can be used to identify those patients in whom a novel pathogenic target may be therapeutically exploited. Excessive degradation of agrin by neurotrypsin leading to fragmentation of the NMJs appears to be an important process in the pathogenesis of sarcopenia.
Conclusions
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Animal model for agrin-dependent sarcopenia-the SARCO mouse Jan 
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The association between sarcopenia and sarcopenic obesity and lipid profile in elderly men Results: Of all men investigated, 31 were sarcopenic and 16 were defined as sarcopenic-obese. There was the weak negative association between muscle mass and total cholesterol (r0−0.34, p00.018) and LDL (r0−0.36, p00.012) in sarcopenic group, but in sarcopenic obesity group muscle mass was not statistically significant associated with lipid profile.
Conclusions: Sarcopenia is associated with serum lipids: total cholesterol and LDL. Larger cohorts of subjects studied are needed to clarify the significance of our finding.
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Muscle-specific atrophy with aging: the AGES-Reykjavik study ability to carry out motor tasks involving postural control.
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Branched-chain amino acid oxidation in skeletal muscle-practical im- Results: Infusion of alanyl-glutamine induced a decrease in plasma BCAA levels, a decrease in leucine oxidation, and an improvement of protein balance due to the decrease in proteolysis both in intact and endotoxemic rats. Ammonium infusion induced an increase in ammonia and glutamine, an increase in BCAA oxidation, a decrease in BCAA and alanine levels in blood plasma, a decrease in whole-body protein turnover, and a decrease in protein synthesis in skeletal muscle.
Conclusions: It is concluded that changes in glutamine synthesis induced by alanyl-glutamine and by ammonia infusion are associated with significant alterations in BCAA and protein metabolism. The results also demonstrate that the cause of decreased plasma BCAA levels observed frequently in liver cirrhosis is hyperammonemia.
Supported by Research Project MSM 0021620820.
6-20
Epidemiological study to assess the prevalence of anorexia-cachexia syndrome in elderly patients Objective: The objectives of this study were to determine the prevalence of anorexia-cachexia syndrome (ACS), and to know the clinical profile, nutritional status, and therapeutic approach of ACS in Spanish elderly patients.
Methodology: This is a multicenter epidemiological study in two phases. decreased muscle strength, fatigue, anorexia, low rate free-fat mass, and biochemical abnormalities. All patients had given written informed consent.
Results: Sixty-six centers distributed for Spain participated in the study.
Four thousand fifty-three (4,153) patients were included in phase A for the prevalence study. Twenty-four percent (24%) had weight loss >5% in the last 12 months. Of these, 15.8% met the diagnostic Evans's criteria for ACS. The results in phase B were: mean age 83 years and concomitant diseases: neoplasia (15.4%), chronic kidney disease (26.8%), COPD (27.5%), diabetes mellitus (30.9%), and chronic heart failure (45.6%).
Nutritional status assessed by the MNA questionnaire indicated that 76.4% of patients were malnourished, 22.3% were at risk of malnutrition.
There was a positive correlation between MNA and the five criteria of Evans. The therapeutic approach followed in these patients showed that 71% received dietary counseling, 40.5% received drug treatment, and 82% of them were already being treated with megestrol acetate.
Conclusions:
The ACS affects 15.8% of the Spanish elderly population.
The ACS is associated with chronic diseases frequent in elderly population such as chronic heart failure, COPD, renal failure, diabetes mellitus, and
cancer. There is a positive correlation between nutritional status and the parameters that define the Evans's criteria of ACS, this allows concluding that these criteria can be a useful tool in clinical practice to diagnose and monitoring these patients. Over 80% of ACS patients with pharmacological treatment received megestrol acetate. Under our knowledge, this is the first study that provides data on the prevalence of SCA in the elderly, using the criteria of Evans as a diagnostic tool. peptide derived from nucleobindin-2. Therefore, we measured the plasma nesfatin-1 levels in AN-R patients to investigate its role in AN-R.
Methods: Fifteen women participated in this study; seven patients with AN-R and eight age-matched healthy controls (average BMI, 13.0±0.3 vs.
21.6 ±0.5, respectively). After overnight fasting, blood samples were obtained from each subject. The levels of nesfatin-1, acyl ghrelin, and des-acyl ghrelin in the samples were measured.
Results: Plasma nesfatin-1 levels were significantly lower in AN-R group than in control group (P<0.05). Plasma acyl ghrelin and des-acyl ghrelin levels were significantly higher in AN-R group than in control group (P< 0.01 and P<0.05, respectively).
Conclusions: Our result indicates that nesfatin-1 is involved in nutrition status.
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The FRAIL scale: a simple scale for diagnosis and predicting frail scales. The FRAIL scale was equivalent or superior to the other scales at predicting incident ADL deficits, incident IADL deficits, and mortality at 9 years. Muscle mass in the frail was 62.32%, pre-frail 61.72%, and nonfrail 65.95% (F014.78, p<0.001; pre-frail versus non-frail p<0.001; frail versus non-frail p<0.05). Fat mass in the frail was 37.68%, pre-frail 38.28%, and non-frail 34.05%. We concluded that the FRAIL scale is an excellent tool for identifying frailty. This research was supported by a grant from the National Institute on Aging to Dr. D. K. Miller (R01 AG-10436).
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Low appendicular skeletal mass (ASM) with limited mobility predicts poor outcomes after 6 years in middle-aged African Americans Methods: Human myotubes were exposed to different AT concentrations ranging from sub-to supratherapeutic (0.1, 1, 10, 100 μM). AT exposure was combined with time-dependant LPS (100 ng/mL) exposure (no exposure, 48-h co-exposure, 24-h pre-exposure, 12-h postexposure) to evaluate for timeof-exposure effects. Constitutive and LPS-induced TNF-alpha production was observed. TNF-alpha concentration was measured using ELISA.
Results: Constitutive TNF-alpha levels were 9.78±1.03 pg/10.000 nuclei.
After exposing myotube cultures to increasing AT concentrations, no effect on TNF-alpha secretion was observed. LPS stimulated TNF-alpha secretion (9.8 vs. 24.5 pg/10,000 nuclei; p<0.01). After co-exposing myotube cultures to LPS and AT, inhibitory effect of AT on LPS-induced TNF-alpha secretion was observed, as well as in cultures pre-exposed to LPS before treatment with AT. However, when myotube cultures were first treated with AT and followed by LPS-exposure controversial stimulatory dose dependent effect of AT on TNF-alpha secretion was observed.
Conclusions: AT does not affect constitutive TNF-alpha secretion in cultured human myotubes, but inhibits LPS-stimulated secretion. Controversial pro-inflammatory AT effect was observed in pre-treatment prior to LPS, suggesting a complex AT effects and involvement of different molecular pathways. Concentration and time-of-exposure seem to be of great importance when considering statin-induced effects on TNF-alpha production.
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Treatment of cancer cachexia-induced cardiomyopathy Furthermore, we analysed the cardiac function and quality of life on days 0 and 10/11. After sacrificing the rats, we measured the weight of the organs and tested the heart for atrophic mechanisms (UPS-system, caspases) and anabolic signaling (Akt pathway).
Results: Treatment of tumor-bearing rats with bisoprolol or spironolactone ameliorated body wasting by maintaining lean and fat mass.
Furthermore, these rats had an improved heart function compared to the placebo group and a better survival (Biso: HR 0.32, p00.0017, Spiro: HR 0.31, p00.0007). Skeletal muscle atrophy is a common and debilitating condition that lacks a pharmacologic therapy. To develop a potential therapy, we identified 63 mRNAs that were regulated by fasting in both human and mouse muscle, and 29 mRNAs that were regulated by both fasting and spinal cord injury in human muscle. We used these two unbiased mRNA expression signatures of muscle atrophy to query the connectivity map, which singled out ursolic acid as a compound whose signature was opposite to signatures of muscle atrophy. A natural triterpene acid, enriched in apple peels, and ursolic acid reduced muscle atrophy in three distinct mouse models: fasting, denervation, and immobilization. Moreover, when administered to mice in the absence of an atrophy-inducing stress, ursolic acid stimulated muscle hypertrophy and increased grip strength. We found that ursolic acid reduced atrophy and stimulated hypertrophy by enhancing skeletal muscle insulin/ IGF-I signaling and inhibiting atrophy-associated mRNA expression.
Importantly, ursolic acid's effects on muscle were accompanied by reductions in adiposity, fasting blood glucose, and plasma cholesterol and trigly- in both HD groups, amount of GSK-3β and Akt significantly changed (p< 0.05) in ARA286 group. Low-dose ARA284 also protected the tissues, but to a lesser extent than high dose. ARA286 in low concentration had no effect. No effect was observed on survival using TPMs.
Conclusions: ARA284 and ARA286 were shown to be effective in reducing tissue wasting in rat cancer cachexia model. These compounds should be seen as prospective drugs for human cancer cachexia.
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MT-102, a new "anabolic catabolic transforming agent", reverses effects of sarcopenia in a rat model Conclusions: MT-102 (3.0 mg/kg/day) reversed effects of ageing, especially loss of muscle mass and increased fat mass. Hence, it is likely to be also a prospective drug to treat patients suffering from sarcopenia.
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MT-102, a new "anabolic catabolic transforming agent", improves survival by a gain of skeletal muscle in a rat model of cancer cachexia Background: Cancer cachexia is associated with impairment in heart function, caused by a progressive loss of heart weight due to a pathologic decrease in size and mass. Atrophy of epicardium with marked diminution and therefore loss of epicardial fat mass is also described, as well as increased pigmentation of myocardium and little or no alteration of endocardium.
Methods: Young male Wistar Han rats (weight approximately 200 g) were intra-peritoneally inoculated with 10 8 Yoshida AH-130 hepatoma cells.
Animals were treated once a day with 0.3 or 3.0 mg/kg MT-102 or placebo.
Echocardiography of heart was determined 1 day before tumour-inoculation and on day 11 of the 16-day protocol. Body weight and body composition (NMR-scan) were analysed 1 day before tumour-inoculation and after sacrifice.
Results: Heart weight was significantly increased in the group treated with 3.0 mg/kg/day MT-102 (573±32 mg vs. placebo 506±8 mg; p<0.001). Heart rate was not significantly affected by 3.0 mg/kg/day MT-102 (326±12 bpm), or 0.3 mg/kg/day MT-102 (327±18 bpm) compared to placebo (366± Moreover, we labelled DFAT cells with nuclear GFP using a lentiviral transduction system.
Results:
We analysed the gene expression profile of DFAT cells in order to characterise their stemness and myogenic potential. To investigate the ability of human DFAT cells to fuse with myocytes in co-culture, we validated a GFP-labelling method based on lentiviral transduction system.
Moreover, we plan to improve the myogenic potential of DFAT cells by lentiviral-mediated forced expression of MyoD in vitro.
Conclusions:
We propose to evaluate the myogenic potential of human DFAT cells in muscle engraftment approaches in a mouse model of cachexia. In summary, we suggest DFAT cells as a potential novel promising source of pluripotent cells available for a new cell therapy approach designed to treat cachexia.
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A phase I study of the effects of a true human, monoclonal antibody against interleukin 1α on lean body mass, nutritional intake and appetite in advanced cancer patients: preliminary findings Introduction: Cancers of the colon and rectum are the third most common forms of cancer worldwide. The prognosis for survival after disease progression is usually poor. Cancer anorexia-cachexia syndrome is prevalent among advanced cancer patients, and has a large impact on morbidity, mortality, and a patient's quality of life. Early intervention with nutritional supplementation has been shown to halt malnutrition, and may improve outcome in some patients. In our study, we assessed the influence of nutritional support (counseling, nutritional supplements, and megestrol acetate) on the nutritional status and symptom prevalence in patients with colorectal cancer during chemotherapy. The study was designed to investigate whether dietary counseling, oral nutrition (commercial supplements), and megestrol acetate during chemotherapy affected nutritional status and survival in patients with colorectal cancer.
Methods: Six hundred and twenty-eight colorectal cancer patients were included in the study from January 2001 through December 2009, and randomized into one of two groups. Group I consisted of 315 patients (50%) who were monitored prospectively and were given nutritional support. Group II included 313 patients without nutritional counseling or nutritional support, in whom data were collected prospectively during a 9-year period of time. Patients were well balanced between the two groups.
After evaluation (Nottingham Screening Tool Score, Appetite Loss Scale, and ECOG PS, weight), all patients in group I received nutritional counseling, oral nutritional food supplements, and megestrol acetate.
Results: After the completion of chemotherapy, there were lower proportions of patients in group I with a BMI<20, NST≥5, loss of appetite, and decreased weight gain. Nutritional counseling, supplemental feeding, and pharmacological support temporarily halted weight loss and improved appetite. This improvement may have implications for patient survival.
Patients with early nutritional support lived 19.1 months while patients in the control group had a survival of 12.4 months (p00.022).
Conclusion:
These results encourage further studies with more specific nutritional supplementation in patients with colorectal cancer.
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